Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2024 Results Conference Call April 29, 2023 4:30 PM ET

Company Participants

Matt Steinberg - Finn Partners
Scott Davis - Chief Executive Officer
Jerome Wong - Chief Financial Officer
Jason Jones - Chief Operating Officer

Conference Call Participants

Sean Lee - H.C. Wainwright
Ben Haynor - Lake Street

Operator

Greetings, and welcome to the Ekso Bionics' First Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce, Matt Steinberg with Finn Partners. Thank you. You may begin.

Matt Steinberg

Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; Jerome Wong, Chief Financial Officer; and Jason Jones, Chief Operating Officer.

Earlier today, Ekso Bionics released financial results for the quarter ended March 31, 2024. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that, management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, or expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to. Accordingly, you should not place undue reliance on these statements.

For a list and description of the risks and uncertainties associated with Ekso's businesses, please see our filings with the Securities and Exchange Commission. Ekso disclaims any obligation, except as required by law, to update or revise any financial or operational projections, its regulatory outlook, or other forward-looking statements, whether because of new information, future events, or otherwise. Any forward-looking statements made on this call speak only as of the date of this call.

I will now turn the call over to Ekso Bionics' Chief Executive Officer, Scott Davis.

Scott Davis

Thank you, Matt. We closed out the first quarter and started the second quarter of 2024 with positive momentum, as we're pleased to receive final payment determination for Medicare reimbursement of our Ekso Indego Personal. Additionally, our results for the quarter reflect continued improvements from both our scalable commercial strategy and operations.